<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<head>
<title>Historic Dates and Events Related to Vaccines and Immunization</title>
<!-- Goes in the <head> section of every page under /subfolder -->
<script type="text/javascript" language="JavaScript">
<!--
var appname = navigator.userAgent.toLowerCase();
var isWin = (appname.indexOf("win") != -1);
var mac = (appname.indexOf("mac") != -1);
var n4 = (document.layers) ? true:false;
var ie = (document.all)? true:false; 
var ver4 =  (navigator.appVersion.substr(navigator.appVersion.lastIndexOf('.') - 1,1) == 4)? true:false;
if (mac && ie && ver4) {
        var macIE4 = true;
}
if (isWin & n4) {
        document.write('<link rel="stylesheet" type="text/css" href="/inc_all/iac_global_ns.css">');
} else {
        document.write('<link rel="stylesheet" type="text/css" href="/inc_all/iac_global.css">');
}
//-->
</script>

<script language="JavaScript">
<!--
var loaded = false;

function imageLoad() {
if (document.images) {
	arrow_y = new Image();arrow_y.src = "/images/arrow_y.gif"
    arrow_r = new Image();arrow_r.src = "/images/arrow_r.gif"
    return (loaded = true);
 }
}

function ShowOff(itemName) {
    if (document.images) {
    document.images[itemName].src = "/images/arrow_y.gif";
    }
}

function ShowOn(itemName) {
    if (document.images && (loaded == true)) {
    document.images[itemName].src = "/images/arrow_r.gif";
}
}
//-->
</script>





<script language="javascript" type="text/javascript" src="/inc_all/dd3.js"></script>
<link rel=stylesheet type="text/css" href="/inc_all/dd3.css">
<link rel=stylesheet type="text/css" href="/inc_all/hh.css">

<script language="JavaScript">

function SetSiteTabs (itemName) {

if (itemName == "siteitem4") {
ShowImage('siteitem4','/images/homepage/healthpro-on-666666.jpg');
ShowImage('siteitem5','/images/homepage/public-on-91A93E.jpg');
ShowImage('siteitem6','/images/homepage/izcoalitions-91A93E.jpg');
}

if (itemName == "siteitem5") {
ShowImage('siteitem4','/images/homepage/healthpro-on-666666.jpg');
ShowImage('siteitem5','/images/homepage/public-on-666666.jpg');
ShowImage('siteitem6','/images/homepage/izcoalitions-91A93E.jpg');
}

if (itemName == "siteitem6") {
ShowImage('siteitem4','/images/homepage/healthpro-on-666666.jpg');
ShowImage('siteitem5','/images/homepage/public-on-91A93E.jpg');
ShowImage('siteitem6','/images/homepage/izcoalitions-666666.jpg');
}
}

function SetSiteTabsBase (itemName) {
ShowImage('siteitem4','/images/homepage/healthpro-on-666666.jpg');
ShowImage('siteitem5','/images/homepage/public-on-91A93E.jpg');
ShowImage('siteitem6','/images/homepage/izcoalitions-91A93E.jpg');
}

function OnClickSites (itemName) {
SetSiteTabsBase(itemName);

if (itemName == "siteitem4") {
document.location.href='http://www.immunize.org';
w.focus();
}

if (itemName == "siteitem5") {
document.location.href='http://www.vaccineinformation.org';
w.focus();
}

if (itemName == "siteitem6") {
var w = window.open('http://www.immunizationcoalitions.org/');
w.focus();
}

return false;
}

function ShowImage(itemName,ImgFileName) {
    if (document.images) {
    document.images[itemName].src = ImgFileName;
    }
}

//-->
</script>
<meta name="DESCRIPTION" content="Vaccine history timeline: The chart displays many of the vaccination related events that have occurred since Jenner's discovery of the smallpox vaccine.">
<meta name="KEYWORDS" content="Vaccine history, vaccine timeline, historic vaccine dates, vaccine discovery, medical discoveries, vaccine development, vaccine policy history, important vaccine dates, immunization events, history of medicine">
<style type="text/css"></style>
</head>

<!-- Outermost table for all pages: body_top_all.inc -->

<body background="http://www.immunize.org/images/homepage/wings.gif" alink="#006B91" link="#006B91" vlink="#006B91"
leftmargin=0 topmargin=0 marginwidth=0 marginheight=0 onload="imageLoad()">
<!-- Outermost table controlling the whole page -->
<div align="center" id="top">
  <table border="0" style="border-collapse: collapse" bordercolor="#CCCCCC" cellspacing="0" width="980" cellpadding="0" bgcolor="#FFFFFF">
    <tr>
      <td><noscript>
<p align="center"><b><font color="#E87610" face="Arial" size="2">This page uses 
&quot;javascript&quot; to display properly.<br>
Javascript is not enabled in your browser, so <br>
some features on this page may not work correctly.</font></b></p></noscript>
<!-- Start of page headers -->

<table width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="#E8E8E8">
        <tr>
          <td height="12"></td>
        </tr>
      </table>
      <table width="100%" border="0" cellspacing="0" cellpadding="0">
        <tr>
          <td width="100%" valign="top" background="/images/homepage/top-curve-corner-grey.jpg"><table width="10%" border="0" cellspacing="0" cellpadding="0">
            <tr>
              <td></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
              <td height="2"></td>
            </tr>
            <tr>
              <td nowrap><table width="20" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td height="10" nowrap><a href="/" style="text-decoration:none"
      class="dkgreyorangelink8">Home</a></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td><b><font size="1" color="#030303" face="Arial">|</font></b></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td style="white-space:nowrap"><a href="/aboutus" style="text-decoration:none" class="dkgreyorangelink8">About IAC</a></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td><b><font size="1" color="#030303" face="Arial">|</font></b></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td nowrap><a href="/aboutus/contactus.asp" style="text-decoration:none" class="dkgreyorangelink8">Contact</a></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td><b><font size="1" color="#030303" face="Arial">|</font></b></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td style="white-space:nowrap"><a href="/a-z" style="text-decoration:none" class="dkgreyorangelink8">A-Z Index</a></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td><b><font size="1" color="#030303" face="Arial">|</font></b></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td style="white-space:nowrap"><a href="/support" style="text-decoration:none" class="dkgreyorangelink8">Donate</a></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td><b><font size="1" color="#030303" face="Arial">|</font></b></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td nowrap><a href="/shop" style="text-decoration:none" class="dkgreyorangelink8">Shop</a></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td><b><font size="1" color="#030303" face="Arial">|</font></b></td>
              <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
              <td nowrap><b><a href="/subscribe" style="text-decoration:none" class="tealorangelink8">SUBSCRIBE</a></b></td>
              <td nowrap><table width="20" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="3"></td>
                  </tr>
              </table></td>
            </tr>
          </table></td>
          <td align="right"><table width="10%" border="0" cellspacing="0" cellpadding="0">
            <tr>
            <td style="cursor:pointer;" onClick="OnClickSites('siteitem4');"
            onMouseOver="SetSiteTabs('siteitem4');return true;"
            onMouseOut ="SetSiteTabsBase('siteitem4');return true;" >
            <img name="siteitem4" border="0" src="/images/homepage/healthpro-on-666666.jpg" align="absmiddle" width="198" height="44"></td>
              <td><table width="2" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="5"></td>
                  </tr>
              </table></td>
            <td style="cursor:pointer;" onClick="OnClickSites('siteitem5');"
            onMouseOver="SetSiteTabs('siteitem5');return true;"
            onMouseOut ="SetSiteTabsBase('siteitem5');return true;" > 
            <img name="siteitem5" border="0" src="/images/homepage/public-on-91A93E.jpg" align="absmiddle" width="119" height="44"></td>              
            <td><table width="2" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="5"></td>
                  </tr>
              </table></td>
            <td style="cursor:pointer;" onClick="OnClickSites('siteitem6');"
            onMouseOver="SetSiteTabs('siteitem6');return true;"
            onMouseOut ="SetSiteTabsBase('siteitem6');return true;" >
            <img name="siteitem6" border="0" src="/images/homepage/izcoalitions-91A93E.jpg" align="absmiddle" width="131" height="44"></td>
            </tr>
          </table></td>
        </tr>
      </table></td>
    </tr>
    <tr>
      <td>

<!-- Outermost border table -->
  <div align="left">
    <table border="0" cellspacing="0" width="100%" cellpadding="0">
    <tr>
    <td width="98%" valign="top">
        
<!-- Start content table -->
<div align="center">
  <center>
    <table border="0" cellspacing="0" width="100%" cellpadding="0">
      <tr>
        <td width="100%">
          <div align="center">
            <center>
               
              <table border="0" cellspacing="0" width="100%" cellpadding="0">
                <tr>
                  <td width="100%">
                    <table border="0" cellspacing="0" width="100%" cellpadding="0">
                        <tr>
                          <td width="100%" height="41" align="right" nowrap bgcolor="#666666"><table width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="#666666">
                            <tr>
                              <td height="25" width="50%" align="left" nowrap bgcolor="#666666"><table width="10%" border="0" cellspacing="0" cellpadding="0">
                                  <tr>
                                    <td height="5"></td>
                                  </tr>
                                </table>
                                <a href="http://www.immunize.org" style="text-decoration: none"> <img border="0" src="/images/space1.gif" align="left" width="6" height="10"> <img border="0" src="/images/space1.gif" align="left" width="3" height="10" /><font face="Arial" size="5" color="#FFFFFF">Immunization Action Coalition</font></a></td>
                              <td valign="middle" style="white-space:nowrap"><table width="100%" border="0" cellspacing="0" cellpadding="0">
                                  <tr>
                                    <td align="right" valign="middle"><form action="http://www.immunize.org/search/" id="cse-search-box">
                                        <div>
                                          <div align="right">
                                            <input type="hidden" name="cx" value="017386553933306082099:5o7di6h-q-e" />
                                            <input type="hidden" name="cof" value="FORID:10" />
                                            <input type="hidden" name="ie" value="UTF-8" />
                                            <input type="text" name="q" size="31" />
                                            <input type="submit" name="sa" value="Search" />
                                          </div>
                                        </div>
                                    </form>
                                        <div align="right">
                                          <script type="text/javascript" src="http://www.google.com/cse/brand?form=cse-search-box&amp;lang=en&amp;sitesearch=true"></script>
                                      </div></td>
                                  </tr>
                              </table></td>
                              <td valign="middle" style="white-space:nowrap"><table width="5" border="0" cellspacing="0" cellpadding="0">
                                <tr>
                                  <td height="3"></td>
                                </tr>
                              </table></td>
                            </tr>
                          </table></td>
                        </tr>
                        <tr>
                          <td align="right" nowrap><div align="center">
                            <center>
                              <table border="0" cellspacing="0" width="100%" cellpadding="0" bgcolor="#666666" style="border-collapse: collapse" bordercolor="#111111">
                                <tr>
                                  <td width="100%" height="5"></td>
                                </tr>
                              </table>
                            </center>
                          </div></td>
                        </tr>
                        <tr>
                          <td height="25" align="right">
                          
                          
                          

                          
                          
<!-- #### Begin Dropdown HTML -->  
              
<div id="wrap">
  <div id="topnav">
    <ul id="sddm">
    <li id="sddm1">
     <a id="m1parent" href="/handouts" onMouseOver="mopen('m1')" onMouseOut="mclosetime()">&nbsp;Handouts for Patients &amp; Staff&nbsp;<br>
     <img id="m1underline" src="/images/underline-blank.gif" align="left" border="0" width="195" height="4" /></a>
       <div id="m1" onMouseOver="mcancelclosetime()" onMouseOut="mclosetime()">
            
        <table class="table-style-round">
        <tr bgcolor="#006B91">      
        <td height="10"><a href="#"><font style="font-size:2px"></font></a></td>
        <td height="10"><a href="#"><font style="font-size:2px"></font></a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-18')" onMouseOut="arrow_off('arr1-18')"><a href="/handouts/view-all.asp"> 
          <img id="arr1-18" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;A-Z</a></td>
          <td onMouseOver="arrow_on('arr1-11')" onMouseOut="arrow_off('arr1-11')"><a href="/handouts/screening-vaccines.asp"> <img id="arr1-11" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Screening Questionnaires&nbsp;&nbsp;&nbsp;&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-01')" onMouseOut="arrow_off('arr1-01')"><a href="/handouts/top-picks.asp"> 
          <img id="arr1-01" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Most Popular</a></td>
          <td onMouseOver="arrow_on('arr1-12')" onMouseOut="arrow_off('arr1-12')"><a href="/standing-orders/"> <img id="arr1-12" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Standing Orders</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-02')" onMouseOut="arrow_off('arr1-02')"><a href="/handouts">
          <img id="arr1-02" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Clinic Resources</a></td>
          <td onMouseOver="arrow_on('arr1-06')" onMouseOut="arrow_off('arr1-06')"><a href="/handouts/vaccine-storage-handling.asp"> <img id="arr1-06" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Storage &amp; Handling</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-03')" onMouseOut="arrow_off('arr1-03')"><a href="/handouts/?f=8"> 
          <img id="arr1-03" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Vaccine Index</a></td>
          <td onMouseOver="arrow_on('arr1-13')" onMouseOut="arrow_off('arr1-13')"><a href="/handouts/vaccine-clinic-supplies.asp"> <img id="arr1-13" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Supplies Checklist</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-04')" onMouseOut="arrow_off('arr1-04')"><a href="/handouts/administering-vaccines.asp"> 
          <img id="arr1-04" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Administering Vaccines</a></td>
          <td onMouseOver="arrow_on('arr1-20')" onMouseOut="arrow_off('arr1-20')"><a href="/handouts/temperature-logs.asp"> <img id="arr1-20" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Temperature Logs</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-21')" onMouseOut="arrow_off('arr1-21')"><a href="/handouts/adult-vaccination.asp"> 
          <img id="arr1-21" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Adult Vaccination&nbsp;&nbsp;</a></td>
          <td onMouseOver="arrow_on('arr1-14')" onMouseOut="arrow_off('arr1-14')"><a href="/handouts/?f=7"> <img id="arr1-14" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Topics of Interest</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-05')" onMouseOut="arrow_off('arr1-05')"><a href="/handouts/document-vaccines.asp"> <img id="arr1-05" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Documenting Vaccination&nbsp;&nbsp;</a></td>
          <td onMouseOver="arrow_on('arr1-15')" onMouseOut="arrow_off('arr1-15')"><a href="/handouts/?f=6"> <img id="arr1-15" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Translations&nbsp;&nbsp;&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-07')" onMouseOut="arrow_off('arr1-07')"><a href="/handouts/discussing-vaccines-parents.asp"> <img id="arr1-07" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Parent Handouts</a></td>
          <td onMouseOver="arrow_on('arr1-16')" onMouseOut="arrow_off('arr1-16')"><a href="/handouts/vaccine-reactions.asp"> <img id="arr1-16" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Vaccine Reactions</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-08')" onMouseOut="arrow_off('arr1-08')"><a href="/handouts/vaccine-schedules.asp"> <img src="/images/homepage/arrow-ffffff.gif" alt="" width="8" height="14" border="0" align="left" id="arr1-08">&nbsp;Patient Schedules&nbsp;&nbsp;</a></td>
          <td onMouseOver="arrow_on('arr1-19')" onMouseOut="arrow_off('arr1-19')"><a href="/handouts/vaccine-summaries.asp"> <img id="arr1-19" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Vaccine Summaries</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-09')" onMouseOut="arrow_off('arr1-09')"><a href="/handouts/vaccine-questions.asp"> <img src="/images/homepage/arrow-ffffff.gif" alt="" width="8" height="14" border="0" align="left" id="arr1-09">&nbsp;Questions and Answers</a></td>
          <td onMouseOver="arrow_on('arr1-17')" onMouseOut="arrow_off('arr1-17')"><a href="/new/handouts.asp"> <img id="arr1-2" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;What's New: Handouts</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr1-10')" onMouseOut="arrow_off('arr1-10')"><a href="/handouts/vaccine-recommendations.asp"> <img id="arr1-10" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Recommendations&nbsp;&nbsp;&nbsp;&nbsp;</a></td>
          <td>&nbsp;</td>
        </tr>
        <tr>      
        <td><a href="#" class="table-corner-a-left"><font style="font-size:3px">&nbsp;</font></a></td>
        <td><a href="#" class="table-corner-a-right"><font style="font-size:3px">&nbsp;</font></a></td>
        </tr>
        </table>

        </div>
    </li>
    
    <li id="sddm2"><a id="m2parent" href="/clinic" onMouseOver="mopen('m2')" onMouseOut="mclosetime()">&nbsp;Clinic Resources&nbsp;<br>
        <img id="m2underline" src="/images/underline-blank.gif" border="0" align="left" width="118" height="4" /></a>
        <div id="m2" onMouseOver="mcancelclosetime()" onMouseOut="mclosetime()">

       <table class="table-style-round">
        <tr bgcolor="#006B91">
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        </tr>
        <tr>
        <td bgcolor="#006B91" onMouseOver="arrow_on('arr2-01')" onMouseOut="arrow_off('arr2-01')"><a href="/clinic/administering-vaccines.asp">
        <img id="arr2-01" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Administering Vaccines&nbsp;&nbsp;</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td width="6" background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td align="left" bgcolor="#006B91"><font face="arial" size="2" color="#FFFFFF">&nbsp;&nbsp;<b>Related Resources:</b></font></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr2-02')" onMouseOut="arrow_off('arr2-02')"><a href="/clinic/coding-billing.asp">
        <img id="arr2-02" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Coding &amp; Billing&nbsp;&nbsp;&nbsp;</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td width="6" background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td onMouseOver="arrow_on('arr2-08')" onMouseOut="arrow_off('arr2-08')"><a href="/askexperts"> 
        <img id="arr2-08" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Ask the Experts&nbsp;&nbsp;&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr2-03')" onMouseOut="arrow_off('arr2-03')"><a href="/clinic/documenting-vaccination.asp">
        <img id="arr2-03" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Documenting Vaccination&nbsp;&nbsp;</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td width="6" background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td onMouseOver="arrow_on('arr2-09')" onMouseOut="arrow_off('arr2-09')"><a href="/resources"> 
        <img id="arr2-09" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Directory of Resources&nbsp;&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr2-05')" onMouseOut="arrow_off('arr2-05')"><a href="/clinic/scheduling-vaccines.asp"> 
		  <img id="arr2-05" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Scheduling Vaccines</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td width="6" background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td onMouseOver="arrow_on('arr2-10')" onMouseOut="arrow_off('arr2-10')"><a href="/publications"> 
        <img id="arr2-10" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;IAC Publications</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr2-06')" onMouseOut="arrow_off('arr2-06')"><a href="/clinic/screening-contraindications.asp"> 
		  <img id="arr2-06" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Screening for Contraindications&nbsp;&nbsp;&nbsp;</a></td>
          <td bgcolor="#006B91">&nbsp;</td>
        <td width="6" background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td onMouseOver="arrow_on('arr2-11')" onMouseOut="arrow_off('arr2-11')"><a href="/photos"> 
        <img id="arr2-11" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Image Library</a></td>
        </tr>
        <tr bgcolor="#006B91">
         <td onMouseOver="arrow_on('arr2-04')" onMouseOut="arrow_off('arr2-04')"><a href="/clinic/storage-handling.asp">
        <img id="arr2-04" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Storage &amp; Handling</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td width="6" background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        
        <td onMouseOver="arrow_on('arr2-13')" onMouseOut="arrow_off('arr2-13')"><a href="/pocketguides"> 
        <img id="arr2-13" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Pocket Guides</a></td>
        
        
        
        
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr2-07')" onMouseOut="arrow_off('arr2-07')"><a href="/clinic/vaccine-recommendations.asp"> <img id="arr2-07" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Recommendations</a></td>
         <td bgcolor="#006B91">&nbsp;</td>
        <td width="6" background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td onMouseOver="arrow_on('arr2-14a')" onMouseOut="arrow_off('arr2-14a')"><a href="/resources/res_powerpoint.asp"> 
        <img id="arr2-14a" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;PowerPoint Slide Sets</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td bgcolor="#006B91">&nbsp;</td>
          <td bgcolor="#006B91">&nbsp;</td>
          <td background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
          <td bgcolor="#006B91">&nbsp;</td>
        <td onMouseOver="arrow_on('arr2-14b')" onMouseOut="arrow_off('arr2-14b')"><a href="/technically-speaking"> 
        <img id="arr2-14b" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Technically Speaking</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td bgcolor="#006B91">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td width="6" background="/images/homepage/vert-whiteline.gif">&nbsp;</td>
        <td bgcolor="#006B91">&nbsp;</td>
        <td onMouseOver="arrow_on('arr2-15')" onMouseOut="arrow_off('arr2-15')"><a href="/reports"> 
        <img id="arr2-15" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Unprotected People Reports&nbsp;&nbsp;&nbsp;&nbsp;</a></td>
        </tr>
        <tr>
        <td><a href="#" class="table-corner-a-left"><font style="font-size:3px">&nbsp;</font></a></td>
        <td bgcolor="#006B91"><font style="font-size:3px">&nbsp;</font></td>
        <td bgcolor="#006B91"><font style="font-size:3px">&nbsp;</font></td>
        <td bgcolor="#006B91"><font style="font-size:3px">&nbsp;</font></td>
        <td ><a href="#" class="table-corner-a-right"><font style="font-size:3px">&nbsp;</font></a></td>
        </tr>
        </table>

        </div>
    </li>
    
    <li id="sddm3"><a id="m3parent" href="/vis" onMouseOver="mopen('m3')" onMouseOut="mclosetime()">&nbsp;Vaccine Information Statements&nbsp;<br>
    <img id="m3underline" src="/images/underline-blank.gif" border="0" align="left" width="210" height="4" /></a>

        <div id="m3" onMouseOver="mcancelclosetime()" onMouseOut="mclosetime()">
      
       <table class="table-style-round">
        <tr>      
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        <td width="120"><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr3-01')" onMouseOut="arrow_off('arr3-01')"><a href="/vis">
        <img id="arr3-01" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Vaccine Index</a></td>
        <td bgcolor="#006B91">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
        </tr>        
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr3-04')" onMouseOut="arrow_off('arr3-04')"><a href="/vis/?f=9">
        <img id="arr3-04" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Translations Index</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        </tr>  
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr3-02')" onMouseOut="arrow_off('arr3-02')"><a href="/vis/vis_english.asp">
        <img id="arr3-02" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;English-language VISs</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr3-03')" onMouseOut="arrow_off('arr3-03')"><a href="/vis/vis_spanish.asp">
        <img id="arr3-03" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Spanish-language VISs&nbsp;&nbsp;&nbsp;</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        </tr>      
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr3-05')" onMouseOut="arrow_off('arr3-05')"><a href="/new/vis.asp">
        <img id="arr3-05" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;What's New: VISs</a></td>
        <td bgcolor="#006B91">&nbsp;</td>
        </tr>
        <tr>      
        <td><a href="#" class="table-corner-a-left"><font style="font-size:3px">&nbsp;</font></a></td>
        <td><a href="#" class="table-corner-a-right"><font style="font-size:3px">&nbsp;</font></a></td>
        </tr>
        </table>
        </div></li>
        
    <li id="sddm4"><a id="m4parent" href="/vaccines" onMouseOver="mopen('m4')" onMouseOut="mclosetime()">&nbsp;Diseases &amp; Vaccines&nbsp;<br>
    <img id="m4underline" src="/images/underline-blank.gif" border="0" align="left" width="145" height="4" /></a>
        <div id="m4" onMouseOver="mcancelclosetime()" onMouseOut="mclosetime()">
       <table class="table-style-round">
        <tr bgcolor="#006B91">
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr4-01')" onMouseOut="arrow_off('arr4-01')"><a href="/anthrax">
        <img id="arr4-01" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Anthrax</a></td>
        <td onMouseOver="arrow_on('arr4-12')" onMouseOut="arrow_off('arr4-12')"><a href="/pertussis">
        <img id="arr4-12" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Pertussis</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr4-02')" onMouseOut="arrow_off('arr4-02')"><a href="/varicella">
        <img id="arr4-02" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Chickenpox (varicella)&nbsp;&nbsp;&nbsp;&nbsp;</a></td>
        <td onMouseOver="arrow_on('arr4-13')" onMouseOut="arrow_off('arr4-13')"><a href="/pneumococcal-pcv">
        <img id="arr4-13" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;PCV</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr4-03')" onMouseOut="arrow_off('arr4-03')"><a href="/diphtheria">
        <img id="arr4-03" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Diphtheria</a></td>
        <td onMouseOver="arrow_on('arr4-14')" onMouseOut="arrow_off('arr4-14')"><a href="/pneumococcal-ppsv">
        <img id="arr4-14" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;PPSV</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr4-07')" onMouseOut="arrow_off('arr4-07')"><a href="/hib"> 
          <img id="arr4-07" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;<i>H. influenzae </i>(Hib)&nbsp;&nbsp;</a></td>
          <td onMouseOver="arrow_on('arr4-15')" onMouseOut="arrow_off('arr4-15')"><a href="/polio"> 
          <img id="arr4-15" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Polio</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr4-04')" onMouseOut="arrow_off('arr4-04')"><a href="/hepatitis-a">
        <img id="arr4-04" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Hepatitis A</a></td>
        <td onMouseOver="arrow_on('arr4-16')" onMouseOut="arrow_off('arr4-16')"><a href="/rabies"> 
        <img id="arr4-16" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Rabies</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr4-05')" onMouseOut="arrow_off('arr4-05')"><a href="/hepatitis-b">
        <img id="arr4-05" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Hepatitis B</a></td>
        <td onMouseOver="arrow_on('arr4-17')" onMouseOut="arrow_off('arr4-17')"><a href="/rotavirus"> 
        <img id="arr4-17" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Rotavirus</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr4-06')" onMouseOut="arrow_off('arr4-06')"><a href="/hpv">
        <img id="arr4-06" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;HPV</a></td>
        <td onMouseOver="arrow_on('arr4-18')" onMouseOut="arrow_off('arr4-18')"><a href="/rubella"> 
        <img id="arr4-18" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Rubella</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr4-08')" onMouseOut="arrow_off('arr4-08')"><a href="/influenza"> 
          <img id="arr4-08" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Influenza</a></td>
          <td onMouseOver="arrow_on('arr4-20')" onMouseOut="arrow_off('arr4-20')"><a href="/smallpox"> 
          <img id="arr4-20" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Smallpox</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr4-09')" onMouseOut="arrow_off('arr4-09')"><a href="/measles"> 
          <img id="arr4-09" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Measles</a></td>
          <td onMouseOver="arrow_on('arr4-21')" onMouseOut="arrow_off('arr4-21')"><a href="/tetanus"> 
          <img id="arr4-21" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Tetanus</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr4-10')" onMouseOut="arrow_off('arr4-10')"><a href="/meningococcal"> 
          <img id="arr4-10" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Meningococcal</a></td>
          
          <td onMouseOver="arrow_on('arr4-19')" onMouseOut="arrow_off('arr4-19')"><a href="/zoster"> 
          <img id="arr4-19" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Zoster (shingles)&nbsp;&nbsp;&nbsp;&nbsp;</a></td>
          
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr4-11')" onMouseOut="arrow_off('arr4-11')"><a href="/mumps"> 
          <img id="arr4-11" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Mumps</a></td>
          <td onMouseOver="arrow_on('arr4-22')" onMouseOut="arrow_off('arr4-22')"><a href="/vaccines"> 
          <img id="arr4-22" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;View All&nbsp;&nbsp;&nbsp;</a></td>
        </tr>
        <tr>      
        <td><a href="#" class="table-corner-a-left"><font style="font-size:3px">&nbsp;</font></a></td>
        <td><a href="#" class="table-corner-a-right"><font style="font-size:3px">&nbsp;</font></a></td>
        </tr>
        </table>
        </div>
    </li>
    
    
        <li id="sddm6"><a id="m6parent" href="/talking-about-vaccines"

        onMouseOver="document.getElementById('sddm6').style.zIndex = 301; mopen('m6')"
        onMouseOut ="document.getElementById('sddm6').style.zIndex = 106; mclosetime()">&nbsp;Talking about Vaccines&nbsp;<br>
       
        <img id="m6underline" src="/images/underline-blank.gif" border="0" align="left" width="157" height="4" /></a>
        <div id="m6"
        onMouseOver="document.getElementById('sddm6').style.zIndex = 301; mcancelclosetime()"
        onMouseOut ="document.getElementById('sddm6').style.zIndex = 106; mclosetime()">

     <table class="table-style-round">
        <tr>      
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr6-01')" onMouseOut="arrow_off('arr6-01')"><a href="/talking-about-vaccines/adjuvants.asp">
        <img id="arr6-01" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Adjuvants</a></td>
        <td onMouseOver="arrow_on('arr6-14')" onMouseOut="arrow_off('arr6-14')"><a href="/talking-about-vaccines/religious-concerns.asp"> <img id="arr6-14" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Religious Concerns&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr6-02')" onMouseOut="arrow_off('arr6-02')"><a href="/talking-about-vaccines/alternative-medicine.asp">
        <img id="arr6-02" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Alternative Medicine&nbsp;</a></td>
        <td onMouseOver="arrow_on('arr6-15')" onMouseOut="arrow_off('arr6-15')"><a href="/talking-about-vaccines/responding-to-parents.asp"> <img id="arr6-15" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Responding to Parents&nbsp;&nbsp;&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr6-03')" onMouseOut="arrow_off('arr6-03')"><a href="/autism">
        <img id="arr6-03" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Autism&nbsp;</a></td>
        <td onMouseOver="arrow_on('arr6-16')" onMouseOut="arrow_off('arr6-16')"><a href="/thimerosal"> <img id="arr6-16" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Thimerosal&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr6-04')" onMouseOut="arrow_off('arr6-04')"><a href="/talking-about-vaccines/countering-dr-sears.asp">
        <img id="arr6-04" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Countering Dr. Sears&nbsp;</a></td>
        <td onMouseOver="arrow_on('arr6-13')" onMouseOut="arrow_off('arr6-13')"><a href="/talking-about-vaccines/multiple-injections.asp"> <img id="arr6-13" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Too Many Vaccines?</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr6-05')" onMouseOut="arrow_off('arr6-05')"><a href="/importance-of-vaccines">
        <img id="arr6-05" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Importance of Vaccines&nbsp;&nbsp;&nbsp;</a></td>
        <td onMouseOver="arrow_on('arr6-17')" onMouseOut="arrow_off('arr6-17')"><a href="/safety"> <img id="arr6-17" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Vaccine Safety</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr6-06')" onMouseOut="arrow_off('arr6-06')"><a href="/talking-about-vaccines/mmr.asp">
        <img id="arr6-06" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;MMR Vaccine</a></td>
        <td>&nbsp;</td>
        </tr>
        <tr>      
        <td><a href="#" class="table-corner-a-left"><font style="font-size:3px">&nbsp;</font></a></td>
        <td><a href="#" class="table-corner-a-right"><font style="font-size:3px">&nbsp;</font></a></td>
        </tr>
        </table>
        </div>
    </li>
    

     
    <li id="sddm5"><a id="m5parent" href="/iztopics"
     onMouseOver="document.getElementById('sddm5').style.zIndex = 301; mopen('m5')"
     onMouseOut ="document.getElementById('sddm5').style.zIndex = 106; mclosetime()">&nbsp;Topics&nbsp;<br>
     <img id="m5underline" src="/images/underline-blank.gif" border="0" align="left" width="56" height="4" /></a>
    
     <div id="m5"
      onMouseOver="document.getElementById('sddm5').style.zIndex = 301; mcancelclosetime()"
      onMouseOut ="document.getElementById('sddm5').style.zIndex = 106; mclosetime()">
      
       <table class="table-style-round">
        <tr>      
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        <td><a href="#"><font style="font-size:2px">&nbsp;</font></a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr5-01')" onMouseOut="arrow_off('arr5-01')"><a href="/adoption">
        <img id="arr5-01" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Adoption - International&nbsp;&nbsp;&nbsp;&nbsp;</a></td>
        <td onMouseOver="arrow_on('arr5-08')" onMouseOut="arrow_off('arr5-08')"><a href="/msm"> <img id="arr5-08" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Men+Men</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr5-02')" onMouseOut="arrow_off('arr5-02')"><a href="/birthdose">
        <img id="arr5-02" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Birth Dose (HepB)</a></td>
        <td onMouseOver="arrow_on('arr5-09')" onMouseOut="arrow_off('arr5-09')"><a href="/needlesafety"> <img id="arr5-09" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Needle Safety</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr5-03')" onMouseOut="arrow_off('arr5-03')"><a href="/dialysis">
        <img id="arr5-03" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Dialysis</a></td>
        <td onMouseOver="arrow_on('arr5-10')" onMouseOut="arrow_off('arr5-10')"><a href="/pregnancy"> <img id="arr5-10" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Pregnancy</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr5-04')" onMouseOut="arrow_off('arr5-04')">
        <a href="/disparities">
        <img id="arr5-04" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Disparities</a></td>
        <td onMouseOver="arrow_on('arr5-11')" onMouseOut="arrow_off('arr5-11')"><a href="/registries"> <img id="arr5-11" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Registries</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr5-05')" onMouseOut="arrow_off('arr5-05')"><a href="/hcw">
        <img id="arr5-05" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Healthcare Personnel</a></td>
        <td onMouseOver="arrow_on('arr5-13')" onMouseOut="arrow_off('arr5-13')"><a href="/tattoos">
        <img id="arr5-13" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Tattoos &amp; Piercings&nbsp;&nbsp;&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
        <td onMouseOver="arrow_on('arr5-06')" onMouseOut="arrow_off('arr5-06')"><a href="/longtermcare">
        <img id="arr5-06" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Long-Term Care</a></td>
        <td onMouseOver="arrow_on('arr5-14')" onMouseOut="arrow_off('arr5-14')"><a href="/travel">
        <img id="arr5-14" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Travel - International&nbsp;&nbsp;&nbsp;&nbsp;</a></td>
        </tr>
        <tr bgcolor="#006B91">
          <td onMouseOver="arrow_on('arr5-07')" onMouseOut="arrow_off('arr5-07')"><a href="/exemptions"> 
          <img id="arr5-07" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;Mandates &amp; Exemptions&nbsp;&nbsp;</a></td>
          <td onMouseOver="arrow_on('arr5-15')" onMouseOut="arrow_off('arr5-15')"><a href="/iztopics"> 
          <img id="arr5-15" src="/images/homepage/arrow-ffffff.gif" border="0" align="left" width="8" height="14">&nbsp;View all</a></td>
        </tr>
        <tr>      
        <td><a href="#" class="table-corner-a-left"><font style="font-size:3px">&nbsp;</font></a></td>
        <td><a href="#" class="table-corner-a-right"><font style="font-size:3px">&nbsp;</font></a></td>
        </tr>
        </table>

        </div>
      </li>
</ul>
</div>

<div style="clear:both"></div>
</div>
                 
                          
                          
<!-- #### End Dropdown HTML -->
               
                          
                          
                          </td>
                        </tr>
                        <tr bordercolor="#111111" bgcolor="#666666">
                          <td height="5"></td>
                        </tr>
                      </table>


<!-- End of page headers -->

 
<div align="left">
        <table border="0" cellspacing="0" width="100%" cellpadding="0">
          <tr>
            <td width="100%">
            <img border="0" src="http://www.immunize.org/images/space1.gif" width="148" height="24"></td>
          </tr>
        </table>
      </div>

<!-- Outermost border table -->
  <div align="left">
    <table border="0" cellspacing="0" width="100%" cellpadding="0">
    <tr>
    <td width="98%" valign="top">
        
<!-- Start content table -->
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><table width="10%" border="0" cellspacing="0" cellpadding="0">
      <tr>
        <td><table border="0" cellspacing="0" width="25" cellpadding="0">
          <tr>
            <td width="100%" height="5"></td>
          </tr>
        </table></td>
        <td nowrap="nowrap"><a href="http://www.immunize.org" style="text-decoration:none" class="greyorangebreadcrumbs8">IAC Home</a></td>
        <td><table border="0" cellspacing="0" width="10" cellpadding="0">
          <tr>
            <td width="100%" height="5"></td>
          </tr>
        </table></td>
        <td><font class="greyorangebreadcrumbs8">|</font></td>
        <td><table border="0" cellspacing="0" width="10" cellpadding="0">
          <tr>
            <td width="100%" height="5"></td>
          </tr>
        </table></td>
        <td nowrap="nowrap"><font class="orangebreadcrumbs8">Vaccine Timeline</font></td>
      </tr>
    </table></td>
  </tr>
  <tr>
    <td height="20" align="left"></td>
  </tr>
</table>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="1"><table border="0" cellspacing="0" width="25" cellpadding="0">
        <tr>
          <td height="13"></td>
        </tr>
    </table></td>
    <td><table width="100%" border="0" cellspacing="0" cellpadding="0">
      <tr>
        <td width="70%"><table width="100%" border="0" cellspacing="0" cellpadding="0">
          <tr>
            <td height="5"><h1 id="h1_black">Vaccine Timeline</h1></td>
          </tr>
          <tr>
            <td height="5" align="right"></td>
          </tr>
        </table>
          <table width="100%" cellspacing="0" cellpadding="5" border="1" style="border-collapse:collapse" bordercolor="#CCCCCC" bgcolor="#006B91">
            <tr>
              <td><h2 id="h2_white">Historic Dates and Events Related to Vaccines and Immunization</h2></td>
            </tr>
          </table>
          <table width="100%" border="0" cellspacing="0" cellpadding="0">
            <tr>
              <td height="5" align="left"></td>
            </tr>

          <tr>
            <td><font face="Arial" size="2">It was not too many years ago when we 
              celebrated the 200th anniversary of Edward Jenner's first smallpox 
              vaccination in 1796. The development of vaccines continued at a fairly 
              slow rate until the last several decades when new scientific discoveries and technologies led to rapid advances in virology, molecular biology, and vaccinology. The chart which follows displays many of the vaccine- and 
              immunization-related events that have occurred since Jenner's critical
              discovery. This list is by no means exhaustive. If 
              you know of an event that you would like us to add, contact us at <a href="mailto:admin@immunize.org" class="tealorangelink10" style="text-decoration:none">admin@immunize.org</a>.</font><br></td>
          </tr>
        </table>
          <table border="0" cellspacing="0" width="100%" cellpadding="0" id="AutoNumber2">
            <tr>
              <td width="100%">&nbsp;</td>
            </tr>
          </table>
          <TABLE WIDTH="100%" cellspacing="0" cellpadding="7" border="1" bordercolor="#CCCCCC">
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="2" face="Arial">Date</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial"><STRONG>Event and related notes</STRONG></FONT></TD>
            </TR>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 10, 2016</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved Vaxchora 
              for the prevention of cholera.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">April 14, 2016</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved changes 
              to vaccine administration&nbsp;schedule for Trumenba vaccine.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">February 5, 2016</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">National Vaccine 
              Program Office released an National Adult Immunization Plan.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">February 1, 2016</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">2016 U.S. recommended 
              immunization schedules&nbsp;for 0 through 18 years and &quot;catch up&quot; 
              published in <i>MMWR</i>.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">January 14, 2016</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved Hiberix 
              for full Hib vaccine&nbsp;series.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">December 14, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA expanded Gardasil 
              9 licensure to include males age 1626 years.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">November 24, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved new 
              injectable influenza vaccine, Fluad, for use in people age 65 
              years and older</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">October 23, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">ACIP published 
              recommendations for the use of serogroup B meningococcal vaccines 
              in adolescents and young adults.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">September 4, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published updated 
              ACIP recommendations regarding the intervals between PCV13 and 
              PPSV23 vaccines for use in immunocompetent adults age 65 years and 
              older</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">August 14, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">WHO published 
              &quot;Recommendations on Vaccine Hesitancy&quot; in special issue of the 
              journal&nbsp;<i>Vaccine</i>.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 19, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">ACIP published 
              recommendations for yellow fever booster doses.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 12, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">ACIP published 
              recommendations for use of serogroup B meningococcal vaccines in 
              people age ten years and older at increased risk for serogroup B 
              meningococcal disease.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 8, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">American Medical 
              Association adopted a new policy&nbsp;that supports ending non-medical 
              vaccine exemptions, including those for healthcare professionals.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">April 29, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">The Pan American 
              Health Organization&nbsp;declared rubella eliminated in the Americas.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">March 27, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published ACIP 
              recommendations for use of 9-valent HPV vaccine.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">March 27, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published new 
              ACIP recommendations for typhoid vaccination.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">March 24, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved 
              Quadracel, a new&nbsp;combination&nbsp;DTaP+IPV&nbsp;vaccine for use in children 
              age 46 years.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">January 23, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC's Health Alert 
              Network issued a health advisory about a multi-state outbreak of 
              measles linked to Disneyland.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">January 23, 2015</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved the use 
              of Bexsero, the second vaccine licensed in the U.S. to prevent 
              serogroup B meningococcal disease.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">December 19, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved Rapivab 
              to treat influenza infection.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">December 11, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved 
              quadrivalent formulation of Fluzone Intradermal inactivated 
              influenza vaccine.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">December 10, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved the use 
              of Gardasil 9 (Merck)&nbsp;9-valent HPV vaccine in the U.S.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">October 29, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved the use 
              of Trumenba in the U.S. to prevent serogroup B meningococcal 
              disease.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">September 19, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published ACIP 
              recommendations for use of PCV13 and PPSV23 vaccines in adults age 
              65 and older.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 20, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published ACIP's 
              recommendations for use of MenACWY-CRM vaccine in children age 
              223 months at increased risk for meningococcal disease.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">May 5, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">WHO Director-General 
              declared the international spread of wild poliovirus in 2014 a 
              Public Health Emergency of International Concern.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">April 25, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC report showed 
              20-year U.S. immunization program spares millions of children from 
              diseases.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">March 24, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA lowered age of 
              licensure for Adacel vaccine administration from age 11 years to 
              10 years.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">February 28, 2014</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published ACIP 
              recommendations for prevention and control of&nbsp;Haemophilus 
              influenzae&nbsp;type b (Hib)&nbsp;disease.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">December 20, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published 
              guidance for HBV protection and postexposure management of 
              healthcare personnel.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">November 15, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published new 
              recommendations for use of Japanese&nbsp;encephalitisvaccine in 
              children.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">September 10, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">National Vaccine 
              Advisory Committee released revised &quot;Standards for Adult 
              Immunization Practice.&quot;</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">August 16, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA extended FluLaval 
              IIV (GlaxoSmithKline) age range to include children and teens age 
              317 years; licenses quadrivalent FluLaval product.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">August 1, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA expanded age 
              indication for Menveo (Novartis) to include infants and toddlers 
              age 2 through 23 months.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">July 19, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC issued updated 
              recommendations for use of VariZIG immune globulin for varicella 
              postexposure prophylaxis.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 28, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC issued 
              recommendations for PCV and PPSV vaccination of children with 
              immunocompromising conditions.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 20, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">ACIP voted to 
              recommend FluBlok influenza vaccine for people age 18 through 49&nbsp; 
              with egg allergy.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 14, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">CDC published 
              recommendations for preventing measles, rubella, congenital 
              rubella syndrome, and mumps.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b>
              <font face="Arial" size="1">June 7, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved Fluzone 
              (sanofi pasteur) as the third quadrivalent influenza vaccine 
              licensed for U.S. use.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">May 17, 2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> Booster 
                dose of yellow fever vaccine not needed, according to WHO. A single dose of vaccine is effective in providing long-term protection from yellow fever.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 22, 
                2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> ACIP recommended a 
                dose of Tdap vaccine during each pregnancy.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 8, 
                2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> UNICEF and WHO 
                condemned attacks on polio vaccination workers in Nigeria.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">January 25, 
                2013</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved use 
                of Prevnar 13 vaccine in older children and teens (6-17 years).</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">December 18, 
                2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> Institute for Safe 
                Medication Practices (ISMP) launched new Vaccine Error Reporting 
                Program.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">December 12, 
                2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved 
                quadrivalent formulation of Fluarix (inactivated influenza vaccine; 
                GlaxoSmithKline).</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">November 20, 
                2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved first 
                seasonal influenza vaccine manufactured using cell culture technology 
                (Flucelvax, Novartis).</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 24, 
                2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> ACIP voted to 
                recommend use of HibMenCY (Menhibrix, GlaxoSmithKline), a new 
                combination (meningococcal and Hib) vaccine, in infants at increased 
                risk for meningococcal disease.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 24, 
                2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> ACIP voted to 
                recommend that pregnant women receive a dose of Tdap during each 
                pregnancy irrespective of the patient's prior history of receiving 
                Tdap.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 24, 2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved 
                HibMenCY (Menhibrix, GlaxoSmithKline), a new combination 
                (meningococcal and Hib) vaccine for infants.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 7, 2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA expanded 
                licensure of PCV13 to include adults ages 50 years and older.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 5, 2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> U.S. Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released a report titled "Vaccines for Children (VFC) Program: Vulnerabilities in Vaccine Management."</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">April 1, 2012</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> United Nations 
                Foundation launched Shot@Life campaign.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">December 30, 
                2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA expanded use of 
                Prevnar 13 (PCV13, Pfizer) vaccine to include people ages 50 and 
                older.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 25, 
                2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> ACIP recommended 
                all 11 to 12 year-old males get vaccinated against HPV.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 21, 
                2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> Addition of 
                history of intussusception as a contraindication for rotavirus 
                vaccination.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">August 25, 
                2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> National survey 
                indicated HPV vaccine rates trail other teen vaccines.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">August 25, 
                2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> Institute of 
                Medicine issued the report titled "Review of Adverse Effects of Vaccines." Overall, 
                the committee concludes that few health problems are caused by or 
                clearly associated with vaccines.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">July 8, 2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved 
                Boostrix (Tdap, GlaxoSmithKline) to prevent tetanus, diphtheria, and 
                pertussis in older people.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">May 19, 2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> CDC hailed 
                vaccinations as one of 10 public health achievements of first decade 
                of 21st century in Morbidity and Mortality Weekly Report (MMWR).</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">April 22, 2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved the 
                first vaccine (Menactra, meningococcal conjugate vaccine, sanofi 
                pasteur) to prevent meningococcal disease in infants and toddlers.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 15, 
                2011</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> HHS releases U.S. 
                National Vaccine Plan, covers activities, goals, and priorities for 
                2010-2015.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">December 22, 
                2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved Gardasil HPV vaccine to include the indication for the prevention of anal cancer.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">August 11, 
                2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> WHO declared end 
                to 2009 H1N1 influenza pandemic.</font></TD>
            </tr>
            <tr>
              <TD align="right" nowrap valign="top"><b><font face="Arial" size="1"> July 10, 2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">First smallpox vaccine 
                for certain immune-compromised populations delivered under Project 
                BioShield.</font></TD>
            </tr>
            <tr>
              <TD align="right" nowrap valign="top"><b><font face="Arial" size="1"> March 19, 2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">ACIP recommended use of a 
                reduced (4-dose) vaccine schedule for PEP to prevent human rabies.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 24, 
                2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved 
                licensure of Pneumococcal 13-valent conjugate vaccine (PCV13), which 
                offers broader protections against <i>Steptococcus pneumoniae</i> infections.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 19, 
                2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved 
                licensure of Menveo (Novartis), meningococcal conjugate vaccine for 
                people ages 11 through 55 years.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">January 29, 
                2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> WHO hailed new 
                Gates Foundation support ($10 billion) as the &quot;Decade of Vaccines.&quot;</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 24, 
                2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> ACIP recommended 
                universal Influenza vaccination for those 6 months of age and older.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 24, 
                2010</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved 
                pneumococcal 13-valent conjugate vaccine (Prevnar 13), which offers 
                broader protection against Streptococcus pneumoniae.</font></TD>
            </tr>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">December 23, 
                2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved 
                high-dose inactivated influenza vaccine (Fluzone High-Dose) for people 
                ages 65 years and older.</font></TD>
            </tr>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">November 16, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> CDC issued Health Advisory 2009 H1N1 Pandemic Update: Pneumococcal vaccination recommended to help prevent secondary infections.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 21, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> Merck issued announcement that the company will not resume production of monovalent measles, mumps, and rubella vaccines.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 16, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved new vaccine (Cervarix, GlaxoSmithKline) for the prevention of cervical cancer.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 16, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved new indication for gardasil to prevent genital warts in men and boys.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">September 15, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved four vaccines against the 2009 H1N1 influenza virus.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">July 1, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> WHO and ACIP issued recommendations on the use of H1N1 influenza vaccines.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 23, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> HHS announced advanced development contract for new way to make flu vaccine.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 11, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> Dr Margaret Chan, Director-General WHO, declared world now at the start of 2009 influenza pandemic.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">May 22, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> HHS directed $1 billion toward development of vaccine for novel influenza A (H1N1).</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">March 16, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> ACIP voted to recommend hepatitis A vaccination for close contacts of international adoptees from countries with high and intermediate endemicity.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 12, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> Vaccine Court ruled that MMR vaccine, when administered with thimerosal-containing vaccines, does not cause autism.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">January 15, 2009</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> HHS awarded a $487 million contract to Novartis Vaccines and Diagnostics, Inc  to build a facility to manufacture cell-based influenza vaccine.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">December 11, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved changes in the schedule for administering anthrax vaccine (BioThrax, manufactured by Emergent BioSolutions) and in the route of administration.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">December 4, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved expanded indication for use of Boostrix Tdap vaccine in people ages 10-64 years.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 27, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> National Quality Forum included the hepatitis B birth dose among its consensus standards for improving health care for mothers and newborns.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 24, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved new DTaP-IPV vaccine (Kinrix) for use in children ages 4-6 years.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 5, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved the use of sanofi pasteur's Tenivac tetanus and diphtheria toxoids adsorbed for adults age 60 years and older. In the original licensure, the age indication was for persons ages 7-59 years.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">April 3, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved new rotavirus vaccine (Rotarix) for use in U.S. Rotarix is a liquid and given in a two-dose series to infants from 6 to 24 weeks of age.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">April 2, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> CDC issued Health Advisory in response to widespread measles outbreaks in U.S.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">March 14, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> CDC updated its recommendations for administering combination MMRV vaccine.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 29, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> CDC announced it had begun distribution of a new-generation smallpox vaccine, ACAM2000 (Acambis, Inc., Cambridge, Massachusetts), to civilian laboratory personnel, the military, and state public health preparedness programs.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">February 27, 2008</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> ACIP voted to expand influenza recommendation to include vaccination for children ages 6 months-18 years.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">December 7, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> CDC published updated recommendation for meningococcal vaccination of at-risk children age 2-10 years in MMWR.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 26, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> ACIP voted to recommend the use of FluMist, the live attenuated influenza vaccine (LAIV; nasal-spray formulation) to include children age 2-5 years.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 19, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> CDC published updated recommendations for prevention of hepatitis A virus infection after exposure and before international travel in MMWR.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">October 18, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved use of Menactra, a bacterial meningitis vaccine, in children age 2-10 years.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">September 28, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved Afluria, a new inactivated influenza vaccine for use in people age 18 years and older.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">September 19, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved use of FluMist nasal-spray influenza vaccine in children age 2-5 years.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">August 10, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> CDC notified MMWR readers of revised recommendations to vaccinate all persons ages 11-18 with MCV4 at earliest opportunity.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">July 20, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> MMWR notified readers that revised International Health Regulations have gone into effect for the United States.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">July 17, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">HHS announced a plan to provide $175 million to assist states in pandemic influenza preparedness efforts.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 27-28, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">ACIP voted to recommend routine use of meningococcal conjugate vaccine in adolescents ages 11-18 years.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 15, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> HHS awarded $132.5 million to sanofi pasteur and MedImmune over five years to retrofit existing domestic vaccine manufacturing facilities on a cost-sharing basis and to provide warm-base operations for manufacturing pandemic influenza vaccines.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">March 28, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2"> FDA approved an accelerated dosing schedule for Twinrix (hepatitis A and B vaccine). The schedule consists of three doses given within three weeks followed by a booster dose at 12 months (0, 7, 21&#150;30 days, 12 months).</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">April 17, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approves first U.S. vaccine for humans 
                against the avian influenza virus H5N1.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">January 7, 2007</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA licensed the refrigerator formulation of 
                FluMist.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 29, 2006</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">ACIP recommends second dose of varicella vaccine 
                for children.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">June 8, 2006</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA licensed the first vaccine developed to 
                prevent cervical cancer (Gardasil by Merck &amp; Co., Inc.), precancerous genital 
                lesions, and genital warts due to human papillomavirus (HPV) types 6, 11, 16, 
                and 18.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">May 25, 2006</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA licensed a new vaccine to reduce the risk of 
                shingles (herpes zoster) in the elderly. The vaccine (Zostavax by Merck &amp; Co., 
                Inc.) is approved for use in people aged 60 years of age and older.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">Feb 24, 2006</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">VariZIG, a new immune globulin product for 
                postexposure prophylaxis of varicella, is available under an Investigational New 
                Drug Application Expanded Access Protocol.</font></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">Feb 3, 2006</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">Rotavirus vaccine, live, oral, pentavalent (RotaTeq 
                by Merck) was licensed for use in infants ages 6 to 32 weeks.</font></TD>
            </TR>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">Dec 19, 2005</font></b></TD>
              <TD><FONT SIZE="2" face="Arial">A final order on the anthrax vaccine was issued 
                by FDA, stating that the licensed anthrax vaccine is safe and effective for the 
                prevention of anthrax disease, regardless of the route of exposure.</FONT></TD>
            </tr>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">Oct 18, 2005</font></b></TD>
              <TD valign="TOP"><font face="Arial" size="2">FDA approved lowering the age limit to 12 mos 
                for the remaining U.S.-licensed hepatitis A vaccine in the U.S. (Havrix by 
                GlaxoSmithKline).</font></TD>
            </TR>
            <tr>
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">Oct 7, 2005</font></b></TD>
              <TD><font face="Arial" size="2">A new Federal Medicare rule became effective 
                that required all long-term care facilities to offer annual vaccination for 
                influenza and one-time vaccination for pneumococcal disease to all residents as 
                a condition of participation in Medicare.</font></TD>
            </tr>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Sept 6, 2005</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A vaccine that combined the measles, mumps, 
                rubella, and varicella antigens (Proquad by Merck) was licensed. The vaccine was 
                indicated for use in children 12 months to 12 years.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Aug 31, 2005</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">An inactivated, injectable influenza vaccine (Fluarix 
                by GlaxoSmithKline) was licensed. The vaccine was indicated for adults 18 years 
                of age and older.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Aug 11, 2005</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">FDA approved lowering the age limit to 12 mos 
                for one of the two licensed hepatitis A vaccine (Vaqta by Merck).</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">June 10, 2005</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">FDA licensed a 2nd Tdap vaccine (Adacel by 
                sanofi pasteur) for use in persons ages 11-64 years.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">May 3, 2005</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">An acellular pertussis vaccine combined with the 
                adult formulation of tetanus and diphtheria (Tdap: Boostrix by GSK) was licensed for use as an active booster in persons 10-18 years of age. This product became 
                the first licensed acellular pertussis-containing vaccine with an indication for 
                adolescents. </FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">April 3, 2005</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">DHHS awarded a contract for $97 million to 
                sanofi pasteur to develop cell culture-based influenza vaccines for the U.S. </FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">March 21, 2005</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">CDC announced that rubella was no longer endemic 
                in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Jan 14, 2005</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first meningococcal polysaccharide (Serogroups 
                A, C, Y and W-135) diphtheria toxoid conjugate vaccine (Menactra by sanofi 
                pasteur) was licensed. This marked the first meningococcal vaccine that was 
                immunogenic and indicated for children younger than 2 years of age.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Aug - Oct, 2004</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A significant shortage of influenza vaccine 
                occurred in the U.S. (History: On August 25, 2004, as a result of routine 
                testing required by FDA, Chiron Corporation, located in the U.K. and one of two 
                suppliers of inactivated influenza vaccine for the U.S., identified bacterial 
                contamination in a limited number of lots (approx 4.5 million doses) of its 
                influenza vaccine. Chiron was expected to produce between 46 and 48 million 
                doses of vaccine for the U.S. as part of a total vaccine supply of about 100 
                million doses. On Oct 4, 2004, authorities in the U.K. suspended the company's 
                license for 3 months. On Oct 16, 2004, FDA announced that none of the influenza 
                vaccine manufactured by Chiron for the U.S. market was safe for use. U.S. 
                authorities recommended allocation of vaccine to those at highest risk of 
                complications from influenza.)</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">May 4, 2004</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The National Institute of Allergy and Infectious 
                Diseases (NIAID), part of the National Institute of Health (NIH), awarded a new 
                license agreement for RotaShield, an oral rotavirus vaccine, created by NIAID 
                scientists in the 1980s. The licensed was awarded to BIOVIRx, Inc., of 
                Minneapolis, MN, which planned global commercialization of RotaShield.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">May 2004</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Contracts were awarded to Aventis Pasteur and to 
                Chiron to develop vaccine against the H5N1 avian influenza virus.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">2004</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The 8th and final report of the Immunization 
                Safety Review Committee was issued by the Institute of Medicine. The report 
                concluded that the body of epidemiological evidence favors rejection of a causal 
                relationship between the MMR vaccine (and thimerosal-containing vaccines) and 
                autism.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">March 24, 2004</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Tetanus and diphtheria toxoids adsorbed for 
                adult use (Decavac by Aventis Pasteur), preservative-free, was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Oct. 15, 2003</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP voted to recommend that children 6 to 23 
                months of age be vaccinated annually against influenza, with implementation 
                scheduled for the fall of 2004.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">2003</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">$81 million was awarded by NIAID through four 
                new contracts to support development of candidate HIV vaccines. The awards were 
                part of NIAID's HIV Vaccine Design and Development Teams program, a 
                public-private partnership that seeks to accelerate HIV vaccine development. The 
                contract recipients were AlphaVAx Human Vaccines, Inc. (Durham, NC), Epimmune, 
                Inc. (San Diego, CA), Novavax, Inc. (Columbia , MD), and Progenics 
                Pharmaceuticals (Tarrytown, NY).</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">2003</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Project Bioshield Act of 2003 was enacted. It 
                authorized more than $5 billion over 10 years to pay for development of 
                vaccines, drugs, and other biomedical countermeasures for biological, chemical, 
                nuclear, and radiological weapons. The Act also empowered the Secretary of 
                Health and Human Services to authorize the use of drugs and vaccines not 
                licensed by the FDA in the event of an act of bioterrorism or other public 
                health emergencies.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">June 17, 2003</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first nasally administered influenza vaccine 
                (FluMist by MedImmune) was licensed. This live influenza A and B virus vaccine 
                was indicated for healthy, non-pregnant persons ages 5-49 years.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 13, 2002</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A vaccine that combined the diphtheria, tetanus, 
                acellular pertussis, inactivated polio, and hepatitis B antigens (Pediarix by 
                GlaxoSmithKline) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">June 21, 2002</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The European Region of the world was certified 
                as polio-free.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">May 14, 2002</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and acellular 
                pertussis vaccine (Daptacel by Aventis Pasteur) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Feb 25, 2002</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">GlaxoSmithKline announced that the company would 
                no longer manufacture or distribute its Lyme disease vaccine, LYMErix, because 
                of insufficient sales of the vaccine.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><font face="Arial" size="1">Dec 13, 2002</font></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">President Bush announced a major smallpox 
                vaccination program to protect the nation against the threat of potential 
                biological warfare. The first phase of the program was targeted to 450,000 
                public health and healthcare personnel, however, the program stalled, with fewer 
                than 40,000 health care workers and emergency responders vaccinated.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">2001</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Bill and Melinda Gates Foundation earmarked 
                $70 million to develop and produce meningitis vaccines tailored for children and 
                adults living in Africa.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">2001</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Following the events of September 11, 2001, IOM 
                again called for creation of a national vaccine authority &quot;&quot;to advance the 
                development, production, and procurement of new and improved vaccines of limited 
                commercial potential but of global public health need.&quot;&quot;</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">May 11, 2001</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A combined hepatitis A inactivated and hepatitis 
                B (recombinant) vaccine (Twinrix by SmithKline Beecham) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Feb 17, 2000</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A 7-valent pneumococcal conjugate vaccine (Prevnar 
                by Wyeth Pharmaceuticals) was licensed for use in infants at 2, 4, 6 and 12-15 
                months of age to prevent invasive pneumococcal disease</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">2000</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Measles was declared no longer endemic in the 
                U.S. following eradication campaigns that began in 1967.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">2000</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Western Pacific Region of the world was 
                certified as polio-free.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 9, 1999</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and acellular 
                pertussis vaccine (Tripedia by Connaught) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Oct 22, 1999</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP voted to withdraw their recommendation for 
                rotavirus vaccine after investigating reports of intussusception (a type of 
                bowel obstruction that occurs when one part of the intestine folds into an 
                immediately adjoining part) in infants within the first two weeks of receipt of 
                the vaccine. Intussusception was found to occur at a rate of approximately 1 
                case for every 5,000 children vaccinated.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Oct 16, 1999</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Wyeth Lederle Vaccines voluntarily withdrew 
                Rotashield from the market.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Fall 1999</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A meningococcal group C conjugate vaccine was 
                introduced into the routine schedule in the U.K. for infants, adolescents (15-17 
                yrs), and college entrants. A second phase was planned to begin in January 2000, 
                subject to availability of vaccine.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Sept 1999</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">FDA approved a 2-dose schedule of hepatitis B 
                vaccination for adolescents 11-15 years of age using Recombivax HB (Merck) with 
                the 10 &micro;g (adult) dose at 0 and 4-6 months later.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">June 17, 1999</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP recommended exclusive use of inactivated 
                poliovirus vaccine (IPV) for infants and children</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1999</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Dale and Betty Bumpers Vaccine Research 
                Center (VRC) was established at the National Institutes of Health to facilitate 
                research in vaccine development. The primary focus of VRC research was to be the 
                development of vaccines for AIDS. </FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1998</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP recommended DTaP vaccines for all five 
                doses in the vaccination schedule, because local reactions, fever, and other 
                systemic events were found to occur substantially less often after DTaP 
                administration than after administration of whole cell DTP.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Aug 26, 1998</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Children's Vaccine Program was established 
                at WHO's Program for Appropriate Technology in Health (PATH) with a $125 
                million gift from the Bill and Melinda Gates Foundation. The program's goal was 
                to provide vaccines to children in the developing world and to accelerate 
                research and development of new vaccines. The first vaccines purchased were Hib, 
                hepatitis B, rotavirus, and pneumococcal, which were not commonly used in the 
                developing world.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 21, 1998</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Lyme Disease Vaccine (Recombinant OspA), (LYMErix 
                by SmithKline Beecham) was licensed for use in persons ages 15 to 70 years. ACIP 
                recommended that decisions on the use of the vaccine be made on the basis of 
                assessment of individual risk, which included the extent of both person-tick 
                contact and geographic risk. Just 3+ years later, on February 25, 2002, 
                GlaxoSmithKline announced that the company would no longer manufacture or 
                distribute LYMErix because of insufficient sales of the vaccine.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Aug 31, 1998</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Rotavirus vaccine, live, oral, tetravalent (RotaShield 
                by Wyeth) was licensed for use in infants at 2, 4, and 6 months of age.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">July 29, 1998</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and acellular 
                pertussis vaccine adsorbed (Certiva by North American Vaccine) was licensed for 
                primary and booster immunization of infants and children (except as a 5th dose 
                in children who have previously received 4 doses of DTaP).</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1998</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first vaccine for the prevention of HIV/AIDS 
                (Aidsvax) entered Phase III trial, the first large-scale human trial of an HIV 
                vaccine. The trial involved more than 5,400 volunteers from the U.S., Canada, 
                and the Netherlands, the majority of whom were men who have sex with men. 
                Preliminary results from the trial AIDS VAX (VaxGen) vaccine were reported in 
                early 2003. The HIV vaccine appeared to show a protective effect among 
                non-Caucasian populations, especially African Americans, although sample sizes 
                were small. However, for the majority of the participants, who were Caucasians, 
                the effect of the vaccine was minimal.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Nov 21, 1997</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The FDA Modernization Act (FDAMA) was signed 
                into law, amending the Food, Drug and Cosmetic Act and the Public Health Service 
                Act to modernize the regulation of food, medical products, and cosmetics. FDAMA 
                initiatives included measures to modernize the regulation of biological 
                products. Specifically, changes included eliminating the need for establishment 
                license applications, streamlining the approval processes for manufacturing 
                changes, and reducing the need for environmental assessment as part of a product 
                application.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1997</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP recommended booster doses of pneumococcal 
                polysaccharide vaccine after 5 years for persons at highest risk of disease.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Oct 20, 1997</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Rabies vaccine (RabAvert by Chiron Behring) was 
                licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Jan 29, 1997</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and acellular 
                pertussis vaccine adsorbed (Infanrix by SmithKline Beecham) was licensed for the 
                first four doses of the series.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Jan 1997</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP recommended adoption of a sequential series 
                of two doses of IPV followed by two doses of OPV for all infants and children to 
                decrease the rare occurrences of Vaccine Associated Paralytic Polio (VAPP) that 
                were noted following the administration of live oral poliovirus vaccine.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 30, 1996</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and acellular 
                pertussis vaccine (Acel-Imune by Lederle) was licensed for use as the first 
                through fifth doses in the series.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Sept 27, 1996</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Combination DTaP and Hib vaccine (TriHIBit by 
                Aventis Pasteur) was licensed for the fourth dose in the DTaP and Hib series.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">July 31, 1996</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and acellular 
                pertussis vaccine adsorbed (Tripedia by Aventis Pasteur) was licensed for 
                primary and booster immunization of infants.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1996</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Interational AIDS Vaccine Initiative (IAVI) 
                was launched, calling for the speedy development of a human immunodeficiency 
                virus (HIV) vaccine for use worldwide. The Initiative created the Scientific 
                Blueprint for AIDS Vaccine Development. Since 1996, IAVI invested nearly $20 
                million in the research and development of HIV vaccines by companies and 
                research institutes worldwide. IAVI received major financial support from the 
                Bill and Melinda Gates Foundation; the World Bank; the Rockefeller, Sloan and 
                Starr foundations; Becton, Dickinson &amp; Co.; and eight national governments, 
                among other donors. IAVI is a Collaborating Centre of the Joint United Nations 
                Programme on HIV/AIDS (UNAIDS).</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Oct 2, 1996</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A combined <EM>Haemophilus influenzae</EM> type 
                b conjugate and hepatitis B vaccine (Comvax by Merck) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Mar 29, 1996</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A second inactivated hepatitis A vaccine (Vaqta 
                by Merck) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Feb 22, 1995</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first inactivated hepatitis A vaccine (Havrix 
                by SmithKline Beecham) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Mar 17, 1995</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Varicella virus vaccine, live (Varivax by Merck) 
                was licensed for the active immunization of persons 12 months of age and older.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1995</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The ACIP, American Academy of Pediatrics, and 
                the American Association of Family Physicians issued the first &quot;harmonized&quot; 
                childhood immunization schedule, combining recommendations of all three national 
                groups.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Nov 28, 1994</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Typhoid Vi polysaccharide inactivated injectable 
                polysaccharide vaccine (Typhim Vi by Aventis Pasteur) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1994</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Global Programme for Vaccines and 
                Immunization was created, merging two WHO programs -- the Expanded Programme for 
                Immunization and the former Programme for Vaccine Development, and adding a new 
                unit for Vaccine Supply and Quality.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1994</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The entire Western Hemisphere was certified as 
                &quot;polio-free&quot; by the International Commission for the Certification of Polio 
                Eradication, WHO.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1993</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Institute of Medicine published &quot;The 
                Children's Vaccine Initiative: Achieving the Vision.&quot; Later, following the 
                events of September 11, 2001, the Institute of Medicine again called for 
                creation of a national vaccine authority &quot;&quot;to advance the development, 
                production, and procurement of new and improved vaccines of limited commercial 
                potential but of global public health need.&quot;&quot;</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1993</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The National Immunization Program (NIP) was 
                created as a separate program reporting directly to the Office of the Director 
                at CDC. NIP was established to provide federal leadership and services to all 
                local and state public health departments involved in immunization activities 
                (e.g., disease surveillance for vaccine-preventable diseases, development of 
                vaccine information management systems).</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">May 1, 1993</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The costs of influenza vaccine and its 
                administration became a covered benefit under Medicare Part B.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">March 1993</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Conjugated <EM>Haemophilus influenzae</EM> type 
                b vaccines (ActHIB by Connaught/M&eacute;rieux and OmniHib by SmithKline Beecham) were 
                licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">March 1993</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A combined <EM>Haemophilus influenzae</EM> type 
                b vaccine and whole cell DTP vaccine (Tetramune by Lederle/Praxis) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1993</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The development of immunization registries was 
                promoted at the national level. A national health goal for 2010 was subsequently 
                established to increase the participation in population-based immunization 
                registries to 95%.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1993</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Vaccines for Children Program was 
                established after passage of the Omnibus Budget Reconciliation Act of 1993. 
                Federally-purchased vaccines under this program were made available to children 
                from birth through 18 years of age who met one of the following requirements: 
                Medicaid-enrolled, without health insurance, and American Indian or Alaskan 
                native. Also, children with health insurance that did not cover the costs of 
                immunization were eligible to receive vaccines at a federally-qualified health 
                center or a rural health clinic. All ACIP recommended vaccines received funding, 
                which included new vaccines, new vaccine combinations, and revised 
                recommendations for vaccine use.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 10, 1992</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Japanese encephalitis (JE) virus vaccine 
                inactivated (JE-Vax by Research Foundation for Microbial Diseases of Osaka 
                University [BIKEN]) was licensed. JE is the leading cause of viral encephalitis 
                in Asia. WHO acts as a facilitator for the development of new JE vaccines that 
                are safer, require fewer doses, and are more suitable for public health use, in 
                particular, in disease-endemic developing countries.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Sept 20, 1992</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and acellular 
                pertussis vaccine (Tripedia by Connaught) was licensed for use as the fourth and 
                fifth doses in the series.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 17, 1991</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and acellular 
                pertussis vaccine (Acel-Imune by Lederle) was licensed for use as the fourth and 
                fifth doses in the series.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Nov 22, 1991</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP recommendations for routine hepatitis B 
                vaccination for all infants were published in <EM>MMWR</EM>.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">August 1991</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The last case of indigenous polio in the Western 
                Hemisphere occurred in a 5-year-old boy, Luis Fermin Tenorio, in Pichanaqui, 
                Peru.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Jan 11, 1991</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Recommendations of ACIP for routine Hib 
                vaccination for infants beginning at 2 months of age were published in <EM>MMWR</EM>.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 21, 1990</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">An enhanced-potency inactivated poliovirus 
                vaccine (Ipol by Pasteur M&eacute;&eacute;rieux Vaccins et Serums) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">April 13, 1990</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP recommendations for use of any of the three 
                licensed Hib conjugate vaccines (ProHIBIT, HibTITER, and PedvaxHIB) for children 
                as young as 15 months of age were published in <EM>MMWR</EM>.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 20, 1989</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Conjugated <EM>Haemophilus influenzae</EM> type 
                b (Hib) vaccine (PedvaxHIB by Merck) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 15, 1989</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A live, oral typhoid vaccine (Ty21a, <EM>Vivotif 
                Berna</EM> by Swiss Serum Institute) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Aug 28, 1989</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Recombinant hepatitis B vaccine (Engerix-B by 
                SmithKline Beecham) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1989</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Recommendations for routine 2nd doses of 
                measles-containing vaccine were issued by both ACIP and the AAP. During the mid- 
                to late-1980s, a high proportion of reported measles cases were in school-aged 
                children (5-19 years) who had been appropriately vaccinated. These vaccine 
                failures led to national recommendations for a second dose of measles-containing 
                vaccine.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 21, 1988</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Conjugated <EM>Haemophilus influenzae</EM> type 
                b vaccine (HibTITER by Wyeth-Lederle) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1988</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Center for Biologics Evaluation and Research 
                (CBER) was created within the FDA to regulate biological products, including 
                blood, vaccines, tissue, allergenics, and biological therapeutics.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1988</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The World Health Assembly (the ministers of 
                health of all member states of the WHO) passed a resolution to eradicate polio 
                by the year 2000.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1988</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The National Vaccine Injury Compensation Program 
                (NVICP) was established to provide compensation following a vaccine-related 
                adverse event that resulted in injury or death. NVICP was intended to serve as 
                an alternative to civil litigation. The law established a Vaccine Injury Table 
                that provided a list of compensable vaccination events and, for each, an 
                associated time period requirement.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Jan 22, 1988</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">ACIP recommendations to administer Hib conjugate 
                vaccine to all children at 18 months of age were published in <EM>MMWR</EM>.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 22, 1987</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Protein-conjugated <EM>Haemophilus influenzae</EM> type b vaccine (PRP-D, ProHibit by Connaught) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">July 23, 1986</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Recombinant hepatitis B vaccine (Recombivax HB 
                by Merck) was licensed. Using recombinant DNA technology, Merck scientists 
                developed a hepatitis B surface antigen subunit vaccine.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1986</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Congress created the National Vaccine Program (NVP) 
                to coordinate the vaccine research and development programs of AID, NIH, CDC, 
                the Department of Defense, and FDA.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1986</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The National Childhood Vaccine Injury Act of 
                1986 was enacted by Congress. The Department of Health and Human Services 
                established the Vaccine Adverse Event Reporting System (VAERS), co-administered 
                by FDA and CDC, to accept all reports of suspected adverse events, in all age 
                groups, after the administration of any U.S.-licensed vaccine. The Act required 
                healthcare providers and vaccine manufacturers to report to the Department of 
                Health and Human Services specific adverse events following the administration 
                of measles, mumps, rubella, polio, pertussis, diphtheria, and tetanus vaccine 
                and any combinations thereof.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Apr 12, 1985</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial"><EM>Haemophilus influenzae</EM> type b (Hib) 
                polysaccharide vaccines (b-CAPSA 1 by Praxis Biologics, Hib-VAX by Connaught, 
                and Hib-IMUNE by Lederle) were licensed. The vaccine was recommended routinely 
                for children at 24 months of age and for children at 15 months of age enrolled 
                in child care facilities. The vaccine was not consistently immunogenic in 
                children &lt;18 months of age.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Sept 1, 1984</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The costs of hepatitis B vaccine and its 
                administration became a covered benefit under Medicare Part B.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">July 1983</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Two enhanced pneumococcal polysaccharide 
                vaccines were licensed (Pneumovax 23 by Merck on July 11 and Pnu-Imune 23 by 
                Lederle on July 21). These vaccines included 23 purified capsular polysaccharide 
                antigens of <EM>Streptococcus pneumoniae </EM>and replaced the 14-valent 
                polysaccharide vaccine licensed in 1977.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1981</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first hepatitis B viral vaccines, developed 
                by Merck and also by the Pasteur Institute, were licensed. Both had 
                independently developed plasma-based hepatitis B viral vaccines.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Nov 23, 1981</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Quadrivalent groups A, C, Y, and W-135 (Menomune 
                A/C/Y/W-135 by Connaught) meningococcal vaccine was licensed. Because this and 
                other polysaccharide meningococcal vaccines were found to induce a relatively 
                poor immune response in children younger than two years and not able to elicit 
                long-term immunologic memory, their use was limited to persons 2 years of age 
                and older.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">July 1, 1981</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The costs of pneumococcal vaccine and its 
                administration became a covered benefit under Medicare Part B.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">May 8, 1980</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The World Health Assembly certified the world 
                free of naturally-occurring smallpox.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1980</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Rabies human diploid-cell vaccine (Imovax Rabies 
                by M&eacute;rieux and Wyvac by Wyeth) were licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1979</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The RA 27/3 (human diploid fibroblast) strain of 
                rubella vaccine (Meruvax II by Merck) was licensed; all other strains were 
                discontinued.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1979</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The last cases of wild type 1 poliovirus 
                occurred in the U.S. among unvaccinated Amish persons and members of other 
                religious groups who did not accept vaccination. The source of the outbreak was 
                determined to have been brought over to the U.S. from the Netherlands by members 
                of an unvaccinated religious group.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Jan 3, 1978</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Yellow fever vaccine (YF-Vax by Connaught) was 
                licensed in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Jan 3, 1978</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Monovalent group A (Menomune-A by Connaught), 
                group C (Menomune-C by Connaught) meningococcal vaccines, and a bivalent vaccine 
                for both groups A and C (Menomune-A/C by Connaught) were licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Nov 21, 1977</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first pneumococcal vaccine was licensed, 
                containing 14 serotypes (of the 83 known serological groups) that comprised 80% 
                of all bacteremic pneumococcal infections in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Oct 26, 1977</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The last case of naturally-acquired smallpox 
                occurred in the Merca District of Somalia.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1977</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Joseph A. Califano, Jr., Secretary of the Dept 
                of Health, Education, and Welfare (later Health and Human Services) launched the 
                National Childhood Immunization Initiative with a goal of achieving 90% 
                vaccination levels among all children. </FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1976</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The age for routine vaccination with MMR vaccine 
                was changed from 12 months to 15 months.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Apr 2, 1974</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first monovalent (group C) meningococcal 
                polysaccharide vaccine (Merck) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1974</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Expanded Programme on Immunization was 
                created within WHO, in response to poor immunization levels in developing 
                countries (less than 5% of children in 1974). The following vaccines are used by 
                the Expanded Programme on Immunization: BCG, polio, DTP, measles (often MMR), 
                yellow fever (in endemic countries), and hepatitis B.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">July 18, 1973</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Measles and mumps virus vaccine, live (M-M-Vax 
                by Merck) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1972</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Division of Biologics Standards was 
                transferred from NIH to FDA and renamed the Bureau of Biologics. It was 
                responsible for the regulation of all biologics, including serums, vaccines, and 
                blood products.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Apr 22, 1971</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Combined measles, mumps, and rubella vaccine (MMR 
                by Merck) as well as combined measles and rubella vaccine (M-R-Vax by Merck) 
                were licensed; the vaccine was developed by Maurice Hilleman and colleagues at 
                Merck.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1971</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">CDC recommended discontinuation of routine 
                vaccination for smallpox in the U.S. following a greatly reduced risk of 
                disease.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1969</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Three rubella virus strains were licensed in the 
                U.S.: HPV-77 strain grown in dog-kidney culture (Rubelogen by Parke-Davis); 
                HPV-77 grown in duck-embryo culture (Meruvax by Merck); and Cendehill strain 
                grown in rabbit-kidney culture (Cendevax by RIT-SKF, and Lirubel and Lirutrin by 
                Dow).</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1968 - 1969</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The &quot;Hong Kong&quot; influenza pandemic, caused by an 
                H3N2 influenza virus, resulted in roughly 34,000 deaths in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1968</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A second live, further attenuated measles virus 
                vaccine (Attenuvax by Merck, based on the Moraten strain, derived from the 
                Edmonston strain) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1967</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Global Smallpox Eradication Program was 
                launched by WHO. During the first year of the program, 44 countries, 31 of which 
                had endemic smallpox, reported 217,218 cases.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Dec 28, 1967</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Mumps virus vaccine live (MumpsVax by Merck) was 
                licensed. The vaccine was developed by Maurice Hilleman who isolated a wild type 
                virus from his daughter, Jeryl Lynn, who was recovering from mumps. It became 
                known as the Jeryl Lynn strain of mumps virus.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1966</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The World Health Assembly called for global 
                smallpox eradication.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1966</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">CDC announced the first national measles 
                eradication campaign. Within 2 years, measles incidence had decreased by more 
                than 90% compared with prevaccine-era levels. </FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1966</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The rubella virus was attenuated by Paul Parkman 
                and Harry Meyer, Jr.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1965</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Bifurcated needle for smallpox vaccine 
                introduced</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1965</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Live, further attenuated measles virus vaccine (Lirugen 
                by Pitman Moore-Dow based on the Schwarz strain, derived from the Edmonston 
                strain) was licensed in the U.S. The recommended age for routine administration 
                was changed from 9 to 12 months of age.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1964</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A rubella epidemic swept the U.S. resulting in 
                12.5 million cases of rubella infection, an estimated 20,000 newborns with 
                congenital rubella syndrome (CRS), and excess fetal and neonatal deaths in the 
                thousands.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1964</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Immunization Practices Advisory Committee (ACIP) 
                to the U.S. Public Health Service was formed to review the recommended childhood 
                immunization schedule and note changes in manufacturers' vaccine formulations, 
                revise recommendations for the use of licensed vaccines, and make 
                recommendations for newly licensed vaccines.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">June 25, 1963</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Trivalent oral polio vaccine was licensed. The 
                vaccine development began in 1957 by Albert Sabin to improve upon the killed 
                Salk vaccine.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1963</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Federal Immunization Grant Program was 
                established. The grants, authorized under section 317 of the Public Health 
                Service Act, were made to states to provide funds to purchase vaccines and to 
                support basic functions of an immunization program. The only vaccines available 
                at the time were DTP, polio, and smallpox.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Mar 21, 1963</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first live virus measles vaccine (Rubeovax 
                by Merck) was licensed. Other live virus measles vaccines were eventually 
                licensed (M-Vac by Lederle, Pfizer-vax Measles-L by Pfizer, and generic vaccines 
                by Lilly, Parke Davis, and Philips Roxane).</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1963</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Inactivated measles vaccine (Pfizer-vax 
                Measles-K by Pfizer and a generic vaccine by Lilly) were licensed in the U.S. 
                These vaccines were eventually withdrawn from the U.S. market in 1967. </FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1962</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">President John F. Kennedy signed the the 
                Vaccination Assistance Act into law. It allowed the CDC to support mass 
                immunization campaigns and to initiate maintenance programs. </FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Mar 27, 1962</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Oral polio vaccine type 3 was licensed in the 
                U.S., as well as the trivalent product.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1961</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Oral polio vaccine types 1 and 2, developed by 
                Dr. Albert Sabin and grown in monkey kidney cell culture, were licensed for use 
                in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1957 - 1958</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The &quot;Asian&quot; influenza pandemic, caused by an 
                H2N2 influenza virus, resulted in an estimated 70,000 deaths in the U.S. alone.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1955</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Polio Vaccination Assistance Act was enacted 
                by Congress, the first federal involvement in immunization activities. It 
                allowed Congress to appropriate funds to the Communicable Disease Center (later 
                the Centers for Disease Control and Prevention) to help states and local 
                communities acquire and administer vaccine.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1955</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Cutter polio vaccine incident began on April 
                25, 1955, when polio was reported in a vaccine recipient. One day later, five 
                more cases were reported. All cases had received vaccine produced by Cutter 
                Laboratories. Polio was reported in 94 vaccinees and in 166 close contacts of 
                vaccinees. On April 27, the Laboratory of Biologics Control requested that 
                Cutter Laboratories recall all vaccine and the company did so immediately. On 
                May 7, the Surgeon General recommended that all polio vaccinations be suspended 
                pending inspection of each manufacturing facility and thorough review of the 
                procedures for testing vaccine safety. The investigation found that live polio 
                virus had survived in two batches of vaccine produced by Cutter Laboratories. In 
                1955, as a result of the Cutter Incident, the Laboratory of Biologics Control 
                was raised to division status within NIH, to strengthen and expand its biologics 
                control function. Large-scale polio vaccinations resumed in the fall of 1955.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">Apr 12, 1955</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first polio vaccine was licensed -- an 
                inactivated poliovirus vaccine (IPV) pioneered by Dr. Jonas Salk.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1954</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Nobel Prize in Medicine was awarded to John 
                Enders, Thomas Weller, and Fredrick Robbins for their discovery of the ability 
                of poliomyelitis viruses to grow in tissue cultures.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1954</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">John Enders and Thomas Peebles isolated the 
                measles virus in cell culture.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1953</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Tetanus and diphtheria toxoids (adult 
                formulation) was first licensed in the U.S., after the concentration of 
                diphtheria toxoid was reduced.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">May 22, 1953</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Yellow fever vaccine (Merrell National Labs) was 
                first licensed in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">July 16, 1952</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Heat-phenol inactivated typhoid vaccine by Wyeth 
                was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1952</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The worst recorded polio epidemic in U.S. 
                history occurred with 57,628 reported cases</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1949</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria and tetanus toxoids and pertussis 
                (DTP) was licensed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1949</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The last case of smallpox in the U.S. was 
                reported; however, it took another two decades before the disease was eradicated 
                globally.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1947</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial"> Combination diphtheria and tetanus toxoids for 
                pediatric use was first licensed in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1945</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Inactivated influenza vaccine was first licensed 
                in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1945</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">K Habel and John Enders isolated the mumps 
                virus.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1944</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Public Health Services Act of 1944 was 
                enacted, consolidating all legislation affecting the functions of the Public 
                Health Service.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1943</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Penicillin first became mass-produced. This 
                medical miracle, rediscovered by Alexander Fleming in 1928, was capable of 
                attacking many types of disease-causing bacteria. It played a vital role in 
                treating infected wounds during World War II.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1942</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Influenza A/B vaccine was introduced to the 
                Armed Forces Epidemiological Board. The influenza vaccine was licensed in 1945 
                and, following the war, was also used for civilians.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1942</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Hepatitis A and B viruses were first 
                differentiated.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1938</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">President Franklin D. Roosevelt, a victim of 
                polio, founded the National Foundation for Infantile Paralysis, later known as 
                the March of Dimes.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1937</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">An adsorbed form of tetanus toxoid was first 
                licensed in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1937</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Division of Biologics Control was formed 
                within the National Institute of Health. Much later, in 1972, the Division was 
                transferred to the FDA.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1935</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">A live yellow fever vaccine (17D) was first 
                licensed. The development of the chorioallantoic membrane for culturing viruses 
                had led to its development.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1930</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Hygienic Laboratory changed its name to the 
                National Institute (singular) of Health and authorized the establishment of 
                fellowships for biological and medical research.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1930</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Cell culture was developed and shown to be able 
                to grow virus, thus paving the way for the subsequent production of viral 
                vaccines.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1928</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first iron lung was used to preserve 
                breathing function in patients with acute polio.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1927</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Bacille Calmette-Guerin (BCG) vaccine was first 
                used in newborns, having been developed by Albert Calmette and Camille Gu&eacute;&eacute;rin 
                in 1921. BCG (live-attenuated <EM>Mycobacterium bovis</EM> BCG) represented the 
                only vaccine against tuberculosis. It has become the most widely administered of 
                all vaccines in the WHO Expanded Programme for Immunization, but has been 
                estimated to prevent only 5% of all potentially vaccine-preventable deaths due 
                to tuberculosis.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1923</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Diphtheria toxoid was licensed; prepared from 
                the inactivated bacterial toxin that has lost its toxicity but retains its 
                antitoxin producing properties. In 1924, Gaston Ramon discovered diphtheria 
                toxoid. Along with the discovery of antitoxins, Ramon uncovered the role of 
                adjuvant substances of immunity.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1918</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The &quot;Spanish flu&quot; influenza pandemic was 
                responsible for 25-50 million deaths worldwide and more than one-half million in 
                the U.S. This virus was unusual because it spread so quickly, was so deadly, and 
                exacted its worse toll among the young and healthy.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1915</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Pertussis vaccine, a suspension of inactivated <EM> Bordetella pertussis</EM> cells, was licensed. Inactivated vaccines were 
                prepared with a microorganism or virus that had been killed, usually with a 
                chemical such as formaldehyde.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1914</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Typhoid vaccine was first licensed in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1914</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Rabies vaccine was first licensed in the U.S.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1914</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Tetanus toxoid was introduced following the 
                development of an effective therapeutic serum against tetanus by Emil Von 
                Behring and Shibasaburo Kitasato.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1908</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first county health departments in the U.S. 
                were formed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1906</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Pure Food and Drugs Act was formed, 
                prohibiting interstate commerce in misbranded and adulterated foods, drinks, and 
                drugs.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">April 5, 1902</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Biologics Control Act was formed. It 
                included the regulation of vaccine and antitoxin producers and required both 
                licensing and inspections of manufacturers. The standards imposed by the 1902 
                Act resulted in bankruptcy for one-third of the companies manufacturing 
                antitoxins and vaccines while benefiting the manufacturers already in 
                compliance. Ten firms held licenses with the Laboratory of Hygiene following the 
                1902 Act.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1901</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">In St. Louis, 13 children died of 
                tetanus-contaminated diphtheria antitoxin. In the autumn of 1901, nine children 
                in Camden, New Jersey, died from tainted smallpox vaccine. Efforts to ensure the 
                purity of biological treatments by government oversight followed with the 
                Biologics Control Act of 1902.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1901</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first Nobel Prize for Physiology and 
                Medicine was awarded to Emil von Behring for his work on the development of a 
                diphtheria antitoxin (later known as antiserum).</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1897</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Plague vaccine was introduced, following the 
                preparation of anti-plague horse serum at the Pasteur Institute by Alexandre 
                Yersin. After demonstrating protection from disease in immunized animals, Yersin 
                went to China with the vaccine to protect humans during a plague epidemic.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1896</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Cholera and typhoid vaccines were first 
                developed.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1893</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">City and state public health departments began 
                mass production of diphtheria antitoxin, following its introduction in European 
                laboratories.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1888</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Pasteur Institute was established as a 
                rabies treatment center as well as an infectious diseases research and training 
                institute.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1888</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The diphtheria toxin was discovered by Emile 
                Roux. Passive serum therapies were developed through the scientific 
                contributions of many, including Emil Von Behring who developed the first 
                effective therapeutic serum against diphtheria and Paul Ehrlich who developed 
                enrichment and standardization protocol, which allowed for an exact 
                determination of quality of the diphtheria antitoxins.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1887</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Joseph Kinyoun established one of the country's 
                first bacteriological laboratories in the Marine Health Service Hospital on 
                Staten Island, NY. He was director of the Laboratory of Hygiene, which moved to 
                Washington, D.C., in 1891. Kinyoun brought the latest techniques such as the 
                procedure for preparing diphtheria antitoxin back from his visits to Europe.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1885</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Louis Pasteur first used rabies vaccine in 
                humans.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1884</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The first live attenuated viral vaccine (rabies) 
                was developed by Louis Pasteur, using dessicated brain tissue inactivated with 
                formaldehyde.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1882</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Robert Koch identified the tubercle bacillus as 
                the cause of tuberculosis, subsequently called Koch's bacillus.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1881</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Louis Pasteur and George Miller Sternberg almost 
                simultaneously isolated and grew the pneumococcus organism.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1879</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Louis Pasteur created the first live attenuated 
                bacterial vaccine (chicken cholera)</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1877</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Louis Pasteur proposed The Germ Theory of 
                Disease.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1798</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Edward Jenner published his work on the 
                development of a vaccination that would protect against smallpox. Two years 
                earlier, in 1796, he had first speculated that protection from smallpox disease 
                could be obtained through inoculation with a related virus, vaccinia or cowpox. 
                He tested his theory by inoculating eight-year-old James Phipps with cowpox 
                pustule liquid recovered from the hand of a milkmaid, Sarah Nelmes.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1798</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The Marine Health Service was established in 
                1798 as the nation's first public health agency. It provided hospital care for 
                merchant seamen and protected port cities against diseases such as smallpox, 
                cholera, and yellow fever.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1721</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Variolation was introduced to Great Britain.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">1100s</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">The variolation technique was developed, 
                involving the inoculation of children and adults with dried scab material 
                recovered from smallpox patients. Variations of variolation have been noted in 
                Turkey, Africa, China, and Europe.</FONT></TD>
            </TR>
            <TR VALIGN="TOP">
              <TD align="right" valign="top" nowrap><b><FONT SIZE="1" face="Arial">400 BC</FONT></b></TD>
              <TD valign="TOP"><FONT SIZE="2" face="Arial">Hippocrates described mumps, diphtheria, 
                epidemic jaundice, and other conditions</FONT></TD>
            </TR>
          </TABLE></td>
        
        
        <table width="100%" border="0" cellspacing="0" cellpadding="0">
            <tr>
              <td height="25"></td>
            </tr>
            <tr>
              <td><font class="bodytext8"><i>This page was updated on June 14, 2016.</i></font></td>
            </tr>
            <tr>
                        <td height="3" align="left" nowrap="nowrap"></td>
                      </tr>
            <tr>
              <td><font class="bodytext8"><i>This page was reviewed on June 7, 2016.</i></font></td>
            </tr>
        </table>
        
        
        
        <td><table border="0" cellspacing="0" width="35" cellpadding="0">
            <tr>
              <td height="12"></td>
            </tr>
        </table></td>
        <td width="30%" valign="top"><table width="100%" border="0" cellspacing="0" cellpadding="0">
          <tr>
            <td align="left"><font size="3" face="Arial" color="#006B91">Related Resources</font></td>
          </tr>
          <tr>
            <td height="3" align="left"></td>
          </tr>
          <tr>
            <td height="2" align="left" bgcolor="#006B91"></td>
          </tr>
          <tr>
            <td height="5" align="left"></td>
          </tr>

            <tr>
              <td height="20"><a href="http://www.historyofvaccines.org/"><img class="badge" src="http://www.historyofvaccines.org/sites/default/files/uploaded-content-images/Vaccines_B_234x60.jpg" alt="" width="234" height="60" /></a></td>
            </tr>
            <tr>
              <td height="5" align="left"></td>
            </tr>
            <tr>
              <td height="20"><font class="bodytext9">Interactive website from the College of Physicians of Philadelphia</font></td>
            </tr>
          </table>
          <table width="100%" border="0" cellspacing="0" cellpadding="0">
            <tr>
              <td height="8" align="left"></td>
            </tr>
            <tr>
              <td align="left" background="/images/homepage/dottedline.jpg"><table border="0" cellspacing="0" width="8" cellpadding="0">
                  <tr>
                    <td height="5"></td>
                  </tr>
              </table></td>
            </tr>
            <tr>
              <td height="10" align="left"></td>
            </tr>
          </table>
          <table width="100%" border="0" cellspacing="0" cellpadding="0">

            <tr>
              <td height="20"><table width="100%" border="0" cellspacing="0" cellpadding="0">
                <tr>
                  <td valign="top"><a href="http://www.nlm.nih.gov/hmd/index.html" target="_blank"><img src="../images/nlm_logo.jpg" alt="History of Medicine" width="100" height="102" border="0" title="History of Medicine"></a></td>
                  <td><table border="0" cellspacing="0" width="8" cellpadding="0">
                      <tr>
                        <td height="12"></td>
                      </tr>
                  </table></td>
                  <td valign="top"><table width="100%" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td><a href="http://www.nlm.nih.gov/hmd/index.html" style="text-decoration:none" class="tealorangelink10">History of Medicine</a></td>
                    </tr>
                    <tr>
                      <td height="3" align="left"></td>
                    </tr>
                    <tr>
                      <td height="20"><font class="bodytext9">NLM collects, preserves, makes available, and interprets for diverse audiences one of the world's richest collections of historical material related to human health and disease.</font></td>
                    </tr>

                  </table></td>
                </tr>
              </table></td>
            </tr>

            <tr>
              <td height="20">&nbsp;</td>
            </tr>
            <tr>
              <td height="20">&nbsp;</td>
            </tr>
            <tr>
              <td height="20">&nbsp;</td>
            </tr>
          </table></td>
      </tr>
    </table>
    </td>
    <td width="1"><table border="0" cellspacing="0" width="25" cellpadding="0">
        <tr>
          <td height="26"></td>
        </tr>
    </table></td>
  </tr>
</table>
<!-- Footer (across content section) for immunize.org -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FFFFFF">
  <tr>
    <td height="15"></td>
  </tr>
  <tr>
    <td height="5" bgcolor="#666666"></td>
  </tr>
  <tr>
    <td><table width="100%" border="0" cellspacing="0" cellpadding="0">
      <tr>
        <td valign="top"><table width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="#FFFFFF">
          <tr>
            <td height="10"></td>
          </tr>
          <tr>
            <td><div align="center">
              <table width="10%" border="0" cellspacing="0" cellpadding="0">
                <tr>
                  <td height="10" style="white-space:nowrap"><a href="http://www.immunize.org/aboutus" class="tealorangelink8" style="text-decoration:none">About IAC</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/aboutus/contactus.asp" class="tealorangelink8" style="text-decoration:none">Contact Us</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/press" class="tealorangelink8" style="text-decoration:none">Press Room</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/citeiac"
      class="tealorangelink8" style="text-decoration:none">Cite IAC</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/linkiac" class="tealorangelink8" style="text-decoration:none">Link to IAC</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/a-z" class="tealorangelink8" style="text-decoration:none">A-Z Index</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/sitemap" class="tealorangelink8" style="text-decoration:none">Site Map</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/iacadmin/disclaimer.asp" class="tealorangelink8" style="text-decoration:none">Disclaimer</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                      <tr>
                        <td height="3"></td>
                      </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                      <tr>
                        <td height="3"></td>
                      </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/aboutus/content-review.asp" class="tealorangelink8" style="text-decoration:none">Content Review</a></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td><font class="bodytext8">&bull;</font></td>
                  <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                    <tr>
                      <td height="3"></td>
                    </tr>
                  </table></td>
                  <td style="white-space:nowrap"><a href="http://www.immunize.org/iacadmin/privacy.asp" class="tealorangelink8" style="text-decoration:none">Privacy</a></td>
                </tr>
              </table>
            </div></td>
          </tr>
          <tr>
            <td height="5"></td>
          </tr>
          <tr>
            <td align="center"><div align="center"><font class="bodytext8">Immunization Action Coalition&nbsp; &bull;&nbsp; 2550 University Avenue West&nbsp; &bull;&nbsp; Suite 415 North&nbsp; &bull;&nbsp; Saint Paul, Minnesota&nbsp; &bull;&nbsp; 55114</font></div></td>
          </tr>
          <tr>
            <td height="5"></td>
          </tr>
          <tr>
            <td align="center"><div align="center"><font class="bodytext8"> tel 651-647-9009 &nbsp;&bull; &nbsp;fax 651-647-9131</font></div></td>
          </tr>
          <tr>
            <td height="5"></td>
          </tr>
          <tr>
            <td align="center"><div align="center"><font class="bodytext8">email </font><a class="tealorangelink8" href="mailto:admin@immunize.org" style="text-decoration:none">admin@immunize.org</a></b></div></td>
          </tr>
          <tr>
            <td height="5"></td>
          </tr>
          <tr>
            <td align="center"><div align="center">
                <table width="10%" border="0" cellspacing="0" cellpadding="0">
                  <tr>
                    <td height="10" style="white-space:nowrap"><a href="http://www.facebook.com/VaccineInformation" target="_blank">
                    <img src="http://www.immunize.org/images/homepage/facebook-20.jpg" border="0" width="20" height="20" /></a></td>
                    <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                          <td height="3"></td>
                        </tr>
                    </table></td>
                    <td><font class="bodytext8">&bull;</font></td>
                    <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                          <td height="3"></td>
                        </tr>
                    </table></td>
                    <td height="10" style="white-space:nowrap"><a href="https://twitter.com/intent/follow?original_referer=http%3A%2F%2Fplatform.twitter.com%2Fwidgets%2Ffollow_button.1379634856.html&amp;partner=undefined&amp;region=follow_link&amp;screen_name=ImmunizeAction&amp;tw_p=followbutton&amp;variant=2.0" target="_blank">
                    <img src="http://www.immunize.org/images/homepage/twitter-20.jpg" border="0" width="20" height="20" /></a></td>
                    <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                          <td height="3"></td>
                        </tr>
                    </table></td>
                    <td><font class="bodytext8">&bull;</font></td>
                    <td><table width="10" border="0" cellspacing="0" cellpadding="0">
                        <tr>
                          <td height="3"></td>
                        </tr>
                    </table></td>
                    <td height="10" style="white-space:nowrap"><a href="http://www.youtube.com/user/ImmunizationAction/" target="_blank">
                    <img src="http://www.immunize.org/images/homepage/youtube_20.jpg" border="0" width="20" height="20" /></a></td>
                  </tr>
                </table>
            </div></td>
          </tr>
          <tr>
            <td>&nbsp;</td>
          </tr>
        </table></td>
      </tr>
    </table></td>
  </tr>
  <tr>
    <td><table width="100%" border="0" cellspacing="0" cellpadding="0">
      <tr>
        <td><table width="15" border="0" cellspacing="0" cellpadding="0">
            <tr>
              <td height="3"></td>
            </tr>
        </table></td>
        <td width="100%"><font class="bodytext8">This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 
        6NH23IP22550) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.</font></td>
        <td><table width="15" border="0" cellspacing="0" cellpadding="0">
            <tr>
              <td height="3"></td>
            </tr>
        </table></td>
      </tr>
    </table>
    </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
  </tr>
</table></td>
      </tr>
    </table>
  </div>



<!-- End Outermost table for all pages: body_bot_all.inc -->
      </td>
    </tr>
  </table>
</div>

<!-- 22 Feb 2010 -->

<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
try {
var pageTracker = _gat._getTracker("UA-12845215-1");
pageTracker._trackPageview();
} catch(err) {}</script>

</body>
</html>